lopinavir has been researched along with Respiratory Syndrome, Acute, Severe in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 3 (12.50) | 24.3611 |
| 2020's | 11 (45.83) | 2.80 |
| Authors | Studies |
|---|---|
| Maxmen, A | 1 |
| Qian, JD; Wang, GQ; Wang, Y; Yao, TT; Zhu, WY | 1 |
| Cao, B; Li, H; Wang, YM; Xu, JY | 1 |
| Wang, Y; Zhu, LQ | 1 |
| Calmy, A; Doherty, M; Ford, N; Norris, SL; Rangaraj, A; Vitoria, M | 1 |
| Dhochak, N; Kabra, SK; Lodha, R; Sankar, J | 1 |
| Atzrodt, CL; Clements, TP; Maknojia, I; McCarthy, RDP; Oldfield, TM; Po, J; Stepp, HE; Ta, KTL | 1 |
| Boutolleau, D; Burrel, S; Calvez, V; Caumes, E; Godefroy, N; Klement-Frutos, E; Lê, MP; Marcelin, AG; Marot, S; Peytavin, G; Pourcher, V | 1 |
| Bai, ZF; Bi, JF; Chen, Z; Ding, JB; Dong, JH; Guo, YM; He, DC; Jiang, TJ; Jing, J; Li, PY; Niu, M; Qin, EQ; Song, XA; Sun, YQ; Tang, JY; Wang, JB; Wang, RL; Wang, ZX; Wu, D; Xiao, XH; Xu, Z; Yang, G; Yu, SM; Zhan, XY; Zhang, P; Zhang, ZT; Zhao, P; Zhao, PF; Zhao, X; Zhou, YF | 1 |
| Einav, S; Servillo, G; Vargas, M | 1 |
| Li, X; Liu, J; Luo, R; Wu, D; Wu, L; Xu, P; Zheng, Y | 1 |
| Al-Tawfiq, JA; Memish, ZA; Mohammed, K; Momattin, H; Zumla, A | 1 |
| Bondarev, VP; Borisevich, SV; Loginova, SIa; Shchukina, VN | 2 |
| Chan, KS; Chu, CM; Lai, ST; Peiris, JS; Que, TL; Sung, J; Tam, CY; Tse, MW; Tsui, E; Wong, MM; Wong, VC; Yuen, KY | 1 |
| Chau, TN; Choi, KW; Chow, TC; Lai, CL; Lai, ST; Lau, T; Lee, KC; Tsang, TY; Tso, YK; Yao, H; Yeung, YC | 1 |
| Chan, KH; Chan, KS; Cheng, VC; Chu, CM; Guan, Y; Hung, IF; Kao, RY; Peiris, JS; Poon, LL; Wong, CL; Wong, MM; Yuen, KY | 1 |
| Tsang, K; Zhong, NS | 1 |
| Cao, Y; Chen, XP | 1 |
| Yap, YL; Zhang, XW | 1 |
| Hui, DS; Wong, GW | 1 |
| Chan, KH; Chen, F; Cheng, VC; Fan, KW; Guan, Y; Hung, IF; Jiang, Y; Kao, RY; Lee, TS; Lu, HT; Peiris, JS; Tsui, WH; Yuen, KY | 1 |
| Guéry, B; Yazdanpanah, Y | 1 |
| Tai, DY | 1 |
13 review(s) available for lopinavir and Respiratory Syndrome, Acute, Severe
| Article | Year |
|---|---|
A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Topics: Animals; Antiviral Agents; Betacoronavirus; Cell Line; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Disease Models, Animal; Humans; Lopinavir; Mice; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Treatment Outcome | 2020 |
Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019.
Topics: Adolescent; Age Factors; Antiviral Agents; Child; Child, Preschool; China; Chloroquine; Coronavirus Infections; COVID-19; Female; Humans; Indoles; Infant; Infant, Newborn; Interferon-alpha; Lopinavir; Male; Pandemics; Pharmaceutical Services; Pneumonia, Viral; Practice Guidelines as Topic; Prognosis; Ribavirin; Risk Assessment; Severe Acute Respiratory Syndrome; Treatment Outcome | 2020 |
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: initial assessment.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus | 2020 |
COVID-19 in Children: Clinical Approach and Management.
Topics: Acute Lung Injury; Antiviral Agents; Betacoronavirus; Child; Child, Preschool; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Disease Outbreaks; Humans; Hydroxychloroquine; Infant; Lopinavir; Palliative Care; Pandemics; Pneumonia, Viral; Protease Inhibitors; Respiratory Distress Syndrome; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; COVID-19 Vaccines; Drug Combinations; Humans; Hydroxychloroquine; Interferon beta-1a; Lopinavir; Middle East Respiratory Syndrome Coronavirus; Pandemics; Respiration, Artificial; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Severity of Illness Index | 2020 |
Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Topics: Antiviral Agents; Betacoronavirus; Clinical Studies as Topic; Coronavirus Infections; COVID-19; Databases, Factual; Humans; Lopinavir; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19.
Topics: Adult; Aged; Antiviral Agents; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Humans; Lopinavir; Male; Middle Aged; Ritonavir; Severe Acute Respiratory Syndrome; Young Adult | 2021 |
Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
Topics: Antiviral Agents; Coronavirus Infections; Humans; Interferon-alpha; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Treatment Outcome | 2013 |
[Experience with empirical treatment of severe acute respiratory syndrome due to coronavirus, genotype IV].
Topics: Antiviral Agents; Drug Therapy, Combination; Humans; Lopinavir; Ribavirin; Ritonavir; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Treatment Outcome | 2011 |
[Present state of in vitro and in vivo studies on efficacy of medical nonspecific protective agents with respect to genotype IV coronavirus causing severe acute respiratory syndrome].
Topics: Animals; Antiviral Agents; China; Chlorocebus aethiops; Disease Reservoirs; Humans; Interferon beta-1b; Interferon Inducers; Interferon-alpha; Interferon-beta; Lopinavir; Ribavirin; Russia; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Vero Cells; Virus Replication | 2011 |
SARS: pharmacotherapy.
Topics: Algorithms; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiviral Agents; Drug Combinations; Humans; Lopinavir; Pyrimidinones; Ribavirin; Ritonavir; Severe Acute Respiratory Syndrome | 2003 |
Advancements in the battle against severe acute respiratory syndrome.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Antiviral Agents; Humans; Interferons; Lopinavir; Protease Inhibitors; Pyrimidinones; Ribavirin; Ritonavir; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Viral Vaccines | 2004 |
[Antiretroviral drugs in severe acute respiratory syndrome].
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Pyrimidinones; Ribavirin; Ritonavir; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Viral Fusion Proteins | 2006 |
2 trial(s) available for lopinavir and Respiratory Syndrome, Acute, Severe
| Article | Year |
|---|---|
Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial.
Topics: Administration, Inhalation; Adult; China; Coronavirus Infections; COVID-19; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Chinese Herbal; Female; Follow-Up Studies; Humans; Integrative Medicine; Interferon-alpha; Lopinavir; Male; Middle Aged; Pandemics; Pneumonia, Viral; Risk Assessment; Severe Acute Respiratory Syndrome; Severity of Illness Index; Survival Rate | 2020 |
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
Topics: Adult; Aged; Cross Infection; Disease Progression; Drug Therapy, Combination; Female; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Odds Ratio; Pyrimidinones; Ritonavir; Severe Acute Respiratory Syndrome; Steroids; Treatment Outcome; Viral Load | 2004 |
9 other study(ies) available for lopinavir and Respiratory Syndrome, Acute, Severe
| Article | Year |
|---|---|
More than 80 clinical trials launch to test coronavirus treatments.
Topics: Adenosine Monophosphate; Alanine; Animals; Anti-HIV Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Dioxanes; Disease Models, Animal; Drug Combinations; Humans; Immunization, Passive; Lopinavir; Medicine, Chinese Traditional; Monosaccharides; Pandemics; Pneumonia, Viral; Registries; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Stem Cell Transplantation; Steroids; Time Factors; Treatment Outcome; World Health Organization | 2020 |
[Potential antiviral therapeutics for 2019 Novel Coronavirus].
Topics: Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; China; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors; Humans; Interferon-beta; Lopinavir; Middle East Respiratory Syndrome Coronavirus; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome | 2020 |
Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19.
Topics: Antiviral Agents; COVID-19; Disease Outbreaks; Humans; Lopinavir; Pneumonia; Prospective Studies; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome; Viral Load | 2021 |
Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Female; Hong Kong; Humans; Lopinavir; Male; Middle Aged; Poisson Distribution; Pyrimidinones; Retrospective Studies; Ritonavir; Severe Acute Respiratory Syndrome; Treatment Outcome | 2003 |
SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases.
Topics: Adult; Anti-Inflammatory Agents; Apoptosis; Biopsy; Coronavirus; DNA, Viral; Drug Combinations; Female; Hepatitis, Viral, Human; HIV Protease Inhibitors; Humans; Liver; Lopinavir; Methylprednisolone; Middle Aged; Mitosis; Pyrimidinones; Ritonavir; Severe Acute Respiratory Syndrome | 2004 |
Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Protease Inhibitors; Hong Kong; Humans; Infectious Disease Transmission, Patient-to-Professional; Lopinavir; Pyrimidinones; Ritonavir; Severe Acute Respiratory Syndrome | 2004 |
Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs.
Topics: Anti-HIV Agents; Antiparasitic Agents; Antipsychotic Agents; Antiviral Agents; Coronavirus 3C Proteases; Cysteine Endopeptidases; Drug Design; Furans; Lopinavir; Molecular Structure; Niclosamide; Promazine; Protease Inhibitors; Protein Binding; Protein Structure, Quaternary; Pyrimidines; Pyrimidinones; Ritonavir; Severe Acute Respiratory Syndrome | 2004 |
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.
Topics: Adult; Antiviral Agents; Cell Line; Chlorogenic Acid; Drug Synergism; Female; Flavonoids; Glycyrrhizic Acid; Humans; Interferon beta-1a; Interferon-alpha; Interferon-beta; Lopinavir; Male; Microbial Sensitivity Tests; Middle Aged; Pyrimidinones; Ribavirin; Rimantadine; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Viral Plaque Assay | 2004 |
Pharmacologic treatment of SARS: current knowledge and recommendations.
Topics: Adrenal Cortex Hormones; Antiviral Agents; Clinical Competence; Disease Outbreaks; Global Health; Humans; Immunoglobulins; Immunologic Factors; Interferons; Lopinavir; Practice Guidelines as Topic; Protease Inhibitors; Pyrimidinones; Ribavirin; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus | 2007 |